Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (BUTTERFLEYE)
Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria, 1407
- Regeneron study Site
-
Sofia, Bulgaria, 1504
- Regeneron study Site
-
Varna, Bulgaria, 9002
- Regeneron study Site
-
-
-
-
Antioquia
-
Medellin, Antioquia, Colombia, 50034
- Regeneron study Site
-
-
Santander
-
Floridablanca, Santander, Colombia, 681004
- Regeneron study Site
-
-
-
-
-
Ostrava-Poruba, Czechia, 708 52
- Regeneron study Site
-
-
-
-
-
Debrecen, Hungary, H-4032
- Regeneron study Site
-
-
-
-
-
Cheonan, Korea, Republic of, 31151
- Regeneron study Site
-
-
-
-
-
Iași, Romania, 700038
- Regeneron study Site
-
-
-
-
-
Moscow, Russian Federation, 119620
- Regeneron study Site
-
Moscow, Russian Federation, 119571
- Regeneron study Site
-
-
Sankt-Peterburg
-
Saint-Petersburg, Sankt-Peterburg, Russian Federation, 194100
- Regeneron study Site
-
-
-
-
-
Bratislava, Slovakia, 833 40
- Regeneron study Site
-
-
-
-
-
Kaohsiung, Taiwan, 81346
- Regeneron study Site
-
-
-
-
-
Khon Kaen, Thailand, 40002
- Regeneron study Site
-
-
Bangkok
-
Pathum Wan, Bangkok, Thailand, 10330
- Regeneron study Site
-
Ratchathewi, Bangkok, Thailand, 10400
- Regeneron study Site
-
-
Chiang Mai
-
Chiangmai, Chiang Mai, Thailand, 50200
- Regeneron study Site
-
-
Songkhla
-
Hat Yai, Songkhla, Thailand, 90110
- Regeneron study Site
-
-
-
-
-
Adana, Turkey, 4522
- Regeneron study Site
-
Ankara, Turkey, 06560
- Regeneron study Site
-
Ankara, Turkey, 06100
- Regeneron study Site
-
Eskisehir, Turkey, 26480
- Regeneron study Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Regeneron study Site
-
-
California
-
La Jolla, California, United States, 92093
- Regeneron study Site
-
Loma Linda, California, United States, 92354
- Regeneron study Site
-
Orange, California, United States, 92868
- Regeneron study Site
-
Palo Alto, California, United States, 94303
- Regeneron study Site
-
San Diego, California, United States, 92123
- Regeneron study Site
-
San Francisco, California, United States, 94143
- Regeneron study Site
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Regeneron study Site
-
-
Georgia
-
Augusta, Georgia, United States, 78705
- Regeneron study Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Regeneron study Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Regeneron study Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- Regeneron study Site
-
Royal Oak, Michigan, United States, 48073
- Regeneron study Site
-
-
New York
-
Bronx, New York, United States, 10462
- Regeneron study Site
-
Brooklyn, New York, United States, 11203
- Regeneron study Site
-
Brooklyn, New York, United States, 11213
- Regeneron study Site
-
Buffalo, New York, United States, 14209
- Regeneron study Site
-
New York, New York, United States, 10029
- Regeneron study Site
-
New York, New York, United States, 10017
- Regeneron study Site
-
Valhalla, New York, United States, 10595
- Regeneron study Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Regeneron study Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Regeneron study Site
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
- Regeneron study Site
-
-
Texas
-
Austin, Texas, United States, 78705
- Regeneron study Site
-
San Antonio, Texas, United States, 78229
- Regeneron study Site
-
San Antonio, Texas, United States, 78240
- Regeneron study Site
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Regeneron study Site
-
-
-
-
-
Ho Chi Minh, Vietnam, 70000
- Regeneron study Site
-
Hue, Vietnam, 100000
- Regeneron study Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Gestational age at birth ≤ 32 weeks or birth weight ≤1500 g
Patients with treatment-naïve retinopathy of prematurity (ROP) classified according to the International Classification for ROP in at least one eye as:
- Zone I Stage 1 plus, or 2 plus, or 3 non-plus or 3 plus, or
- Zone II Stage 2 plus or 3 plus, or
- Aggressive posterior retinopathy of prematurity (AP-ROP)
Key Exclusion Criteria:
- Known or suspected chromosomal abnormality, genetic disorder, or syndrome
- Previous exposure to any Intravitreal (IVT) or systemic anti-vascular endothelial growth factor (VEGF) agent, including maternal exposure during pregnancy and/or during breastfeeding
- Clinically significant neurological disease (eg, intraventricular hemorrhage grade 3 or higher, periventricular leukomalacia, congenital brain lesions significantly impairing optic nerve function, severe hydrocephalus with significantly increased intracranial pressure)
- Pediatric conditions rendering the infant ineligible for study intervention at baseline or for repeated blood draws as evaluated by a neonatal intensive care unit specialist and a study ophthalmologist
- Presence of active ocular infection within 5 days of the first treatment
- Advanced stages of ROP with partial or complete retinal detachment (ROP stage 4 and stage 5)
- ROP involving only Zone III
NOTE: Other protocol defined inclusion/exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Aflibercept Group
Patients will receive a single intravitreal (IVT) injection per eligible eye at baseline.
|
Administered IVT
Other Names:
|
|
Experimental: Laser Group
Patients will undergo laser treatment in each eligible eye at baseline.
|
Transpupillary conventional laser will be administered according to standard local procedures.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age
Time Frame: Baseline to week 52 of chronological age
|
Active ROP was ROP requiring treatment and unfavorable structural outcome was defined as retinal detachment, macular dragging, macular fold, or retrolental opacity.
For participants with both eyes enrolled in the study, both eyes must have met the endpoint.
Participants with only one study eye enrolled were responders if the respective eye responded.
|
Baseline to week 52 of chronological age
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Requiring Intervention With a Second Treatment Modality From Baseline to Week 52 of Chronological Age
Time Frame: Baseline to to week 52 of chronological age
|
Second treatment modality includes any treatment in addition to that assigned to the participant at baseline.
This includes per-protocol rescue treatment (laser for aflibercept group, aflibercept for laser group), anti-VEGF agents not part of study protocol (e.g., bevacizumab, ranibizumab, commercially-available aflibercept not provided as study medication), or any ocular surgery for the management of any retinal pathology secondary to ROP (e.g., victrectomy, scleral buckle for retinal detachments).
|
Baseline to to week 52 of chronological age
|
|
Percentage of Participants With Recurrence of ROP Through Week 52 of Chronological Age
Time Frame: Baseline to week 52 of chronological age
|
Recurrence of disease is defined as the reappearance of the disease requiring further treatment (including retreatment or rescue), where both "presence of ROP" and "presence of active ROP requiring treatment" are marked as "Yes", after initial regression.
Here, the initial regression is defined as, at a particular visit, absence of ROP or ROP treatment not required for active ROP, i.e., presence of ROP is marked as "No" or the presence of active ROP requiring treatment is marked as "No."
|
Baseline to week 52 of chronological age
|
|
Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time Frame: Baseline to Week 52 of chronological age
|
Baseline to Week 52 of chronological age
|
|
|
Percentage of Participants With Systematic (Non-ocular) TEAEs and TESAEs
Time Frame: Baseline to Week 52 of chronological age
|
Baseline to Week 52 of chronological age
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Infant, Newborn, Diseases
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Infant, Premature, Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Retinal Diseases
- Premature Birth
- Retinopathy of Prematurity
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Aflibercept
Other Study ID Numbers
Other Study ID Numbers
- VGFTe-ROP-1920
- 2019-001764-29 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.